

**An Important Message from
The Texas Health and Human Services Commission (HHSC)**

Clinical Prior Authorizations Updates and Implementations

Clinical Prior Authorizations Updates and Implementations.

Background:

HHSC will implement the Cytokine and cell-adhesion molecule (CAM) Antagonists, Pulmonary Hypertension Agents, and Topical Immunomodulators clinical prior authorizations and revise the Calcitonin Gene-Related Peptide Receptor (CGRP) Antagonists, Prophylaxis clinical prior authorization criteria.

Key Details:

On July 27, 2023, HHSC will implement Fee-For-Service updates for Cytokine and CAM Antagonists, Pulmonary Hypertension Agents, and Topical Immunomodulators clinical prior authorizations. Additionally, HHSC will make clarifying revisions for Qulipta in the CGRP Antagonists, Prophylaxis prior authorization criteria guide.

The implementation will include the following updates:

- [Cytokine and CAM Antagonists:](#)
 - Adding the prior authorization criteria for Sotyktu as approved by the Drug Utilization Review (DUR) Board in April 2023
 - Changing the subheading for the Cibinqo Dosing Guideline table from “Recommended Dosing Table” to “Maximum Recommended Dose”
 - Adding the maximum recommended dose for Cytochrome P450 2C19 (CYP2C19) poor metabolizers to the table
 - Adding generic code numbers (GCNs) for Amjevita (a Humira biosimilar product) to the Humira and Biosimilar Agents to the Drugs Requiring Prior Authorization table (GCNs: 42639, 42637, 42592)
- [Pulmonary Hypertension Agents:](#)
 - Adding GCNs for epoprostenol (33243, 30168) and Orenitam ER (43521).
- [Topical Immunomodulators:](#)
 - Adding a check for the application site for Elidel and Protopic 0.3%
 - Updating the approval timeframe for Opzelura to 180 days

As a reminder, HHSC will implement the Qulipta criteria in the CGRP Antagonists, Prophylaxis prior authorization on June 27 for fee-for-service. The clarifying revisions to address Qulipta’s appropriate dosing are included in the criteria logic and the criteria logic diagram of the latest version of the criteria guide.

These clinical prior authorizations are optional for MCOs.

Added Note: UnitedHealthcare Community Plan of Texas will implement the revised criteria by July 27, 2023.

Questions?

Please contact your physician advocate or call UnitedHealthcare Provider Services, toll-free, at 888-887-9003, 8 a.m.–6 p.m. CT, Monday–Friday.